BioNxt Solutions Inc.
BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis; BNT23002 for the treatment of myasthenia gravis; BNT24002, a sublingual thin film for the treatment of lupus nephritis; BNT24003 for the treatment of rheum… Read more
BioNxt Solutions Inc. (BNXTF) - Total Liabilities
Latest total liabilities as of September 2025: $9.54 Million USD
Based on the latest financial reports, BioNxt Solutions Inc. (BNXTF) has total liabilities worth $9.54 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BioNxt Solutions Inc. - Total Liabilities Trend (2018–2024)
This chart illustrates how BioNxt Solutions Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
BioNxt Solutions Inc. Competitors by Total Liabilities
The table below lists competitors of BioNxt Solutions Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CHOROKBAEM COMPANY Co. Ltd
KQ:052300
|
Korea | ₩80.01 Billion |
|
PharmGen Science Inc
KO:004720
|
Korea | ₩83.70 Billion |
|
Cuprum
SN:CUPRUM
|
Chile | CL$280.71 Billion |
|
Chinese Gamer International
TWO:3083
|
Taiwan | NT$115.89 Million |
|
Datavault AI Inc.
NASDAQ:DVLT
|
USA | $39.15 Million |
|
Vittia Fertilizantes
SA:VITT3
|
Brazil | R$312.37 Million |
|
Prestige Biologics Co. Ltd.
KQ:334970
|
Korea | ₩147.13 Billion |
|
Westhaven Ventures Inc
V:WHN
|
Canada | CA$2.67 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down BioNxt Solutions Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 7.78 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioNxt Solutions Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioNxt Solutions Inc. (2018–2024)
The table below shows the annual total liabilities of BioNxt Solutions Inc. from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $8.43 Million | +28.71% |
| 2023-12-31 | $6.55 Million | +14.10% |
| 2022-12-31 | $5.74 Million | -28.75% |
| 2021-12-31 | $8.06 Million | +88.34% |
| 2020-12-31 | $4.28 Million | +83.45% |
| 2019-12-31 | $2.33 Million | +99.37% |
| 2018-12-31 | $1.17 Million | -- |